Member Info for Celtic007

Thanks citizen .. appreciated

Laz, they know what they are doing, trust me. If our 1801 shows brilliant results, then the market can react anyway it wants.

A brilliant tyk2 drug, does not change from one pharmaceutical to another. It has a value, that given to other similar drugs in that class. If someone wants , they will have to pay the market rate for the drug. Simples

I love the way these two interact, like total strangers to their harrowing holding of these pretend shares lol.

No worries,stevej..lol.

Hi laz. I think Stevej meant sareum selling themselves, not telling shareholders here to sell now. He is a good poster.

I think it's best sometimes, to keep quiet, funny guy. Your posting history here, speaks volumes. We are all having a debate, not ramping.

Basser, exactly my point. Here are a few points to remember

1 The tyk2 market is hot

2 we have two molecules and the only one in cancer. This is to a lot of experts here is the big one.

3_ both molecules oral

4 looks like safe data for 1801

5_ if bio markers shown for our 1801 is diverse, then why would a pharmaceutical risk leaving it for others to take.

6 ALL THE BIG Pharmaceuticals ARE CRYING TO SPEND THEIR CASH. BASICALLY, IF YOU HAVE AMAZING DATA, THEN WE WANT YOU.

Thanks potnak. Let's see. Would love a takeover at a good price, but a on license , if it happens, hope it's a big pharmaceutical.

Potnak, your posts can be so negative " leave the lights on". I HAVE SAID, IF DATA RESULTS Don't ATTRACT THE BIG BOYS , THEN TIME TO WORRY. I AM CONFIDENT, THAT WILL NOT BE THE CASE.

Potnak, good points. It will all come down to what indications or biomarker data we show and how appealing this is to a respective acquirer. This is a hot area, and they all want in, and we have two of these molecules. A lot here forget that.

A TO cannot be disregarded. Soon find out.

The market does not like unknowns, and I agree that puts a shadow over the good news recently. At least we know, changes in upper management are happening, and soon find out why.

A offer at this moment with data results will be £3-£4.50 area, goes through next stage then higher as risk reduced.

£3.50 at moment is a bargain...

Two tyk2 molecules, both safe and chk1

Agree sadoldgit. Remember, if this data results are good and indicate good biomarker data, then a big pharmaceutical will be tempted to say make move now. The benefit, is you get the tyk2 and chk1 thrown in for say 500million to 1 billion at least. That is cheap, given the prize here.

It's what they do mike. Bunch of zombies. A few still on here, though I suspect. I expect moaning very soon this week, from a few, if no RNS.

Exactly krone. If data results are good, am sure someone out there will be tempted to snap up these two molecules. What is 500 million to one billion to a large pharmaceutical, when given the pressure of ensuring that they do not lose any market to rivals.

Very excited for data results

Exactly brighty. The pharmaceuticals are desperate to fill the void left over by the patents expiring. All about the data results, hopefully this week as sadoldgit suspects

Hi sadoldgit. I thought the next part was taking place in Australia. I would hope it is, as surely, we are dealing with a regulatory authority that actually does, what it says and is competent, unlike our MHRA. Also, more streamlined, as no change in people involved to scrutinise and advise us.

Don't bother with the weirdos here Gus, best to keep quiet and not interact with them. It feels good, as the majority on this board are real investors, so easy to spot the fakes here.

Good luck. Also use the report button, which I have enjoyed doing recently.

Thanks potnak. Have known you a long time here and you are a genuine guy and I have respect for you . You and me both have a bought a few lemons on aim.

All the best. As I said a few days ago, if data results do not get the majors interested , especially when this area is hot, then something stinks.

Am confident we will equal or better as does sadoldgit, on psoriasis, which in itself is a big market . We will fail many other indications but also hit many other indications.

Next few weeks interesting .

Thanks

Potnak is entitled to his opinion, as he is a holder and I respect that. Just unfortunately also trading it. Fair enough.

Potnak...what would be a low TO OFFER?